Ammonia Solution, Strong

Ammonia Solution, Strong

SCHEMBL2956206

CN(C)c1ccc(-n2c(=O)ccc3c(Nc4ccccc4)c(C(=O)O)sc32)cc1.N

nearest known ligand 0.38

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSF1R P07333 2/20 0.38
KDM1A O60341 5/20 0.37
MAPT P10636 3/20 0.36
TP53 P04637 2/20 0.36
THRB P10828 1/20 0.36
PMM2 O15305 1/20 0.36
MPI P34949 1/20 0.36
PHOSPHO1 Q8TCT1 1/20 0.36
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
USP2 O75604 1/20 0.35
TLR9 Q9NR96 1/20 0.35
BTK Q06187 1/20 0.35
LMNA P02545 1/20 0.35
POLB P06746 1/20 0.35
MAPK8 P45983 1/20 0.34
GAA P10253 2/20 0.34
RAB9A P51151 2/20 0.34
KAT2B Q92831 1/20 0.34
KCNK3 O14649 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Ammonia Solution, Strong SCHEMBL1267334 0.89 CDK4 (0.38) CSF1RMAPTTP53THRBMEN1
SCHEMBL2952230 0.88 KDM1A (0.37) CSF1RKDM1AMAPTTP53THRB
SCHEMBL2957153 0.87 MEN1 (0.46) CSF1RMAPTMEN1KMT2ABTK
SCHEMBL2950110 0.86 TERT (0.37) CSF1RMAPTTP53TLR9BTK
SCHEMBL2950157 0.84 CXCR2 (0.40) MAPTTP53MEN1KMT2AUSP2
SCHEMBL2956215 0.82 PARP1 (0.42) MAPTMEN1KMT2ABTKLMNA
SCHEMBL2957695 0.81 CXCR2 (0.40) CSF1RMAPTTP53THRBMEN1
SCHEMBL2958436 0.81 KMT2A (0.41) CSF1RMAPTMEN1KMT2ATLR9
SCHEMBL2949462 0.80 ADORA2B (0.38) CSF1RMAPTTP53LMNAMAPK8
SCHEMBL2954144 0.80 ALDH1A1 (0.44) TP53MEN1KMT2ALMNAPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7763729-B2 Bicyclic heteroaromatic derivatives UCB PHARMA S.A. (BE) 2010-07-27 US disclosed
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives CELLTECH R&D LIMITED (GB) 2009-02-12 US disclosed
US-7423047-B2 Arylamine substituted bicyclic heteroaromatic compounds as p38 kinase inhibitors CELLTECH R&D LIMITED (GB) 2008-09-09 US disclosed
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors UCB PHARMA S.A. (BE) 2006-01-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060004025-A1 Arylamine substututed bicyclic heteroaromatic compounds as p38 kinase inhibitors MAPK1, CNKSR1, ALK CSF1R 412/4885KDM1A 459/4885MAPT 4305/4885
US-20090042877-A1 Bicyclic Heteroaromatic Derivatives MAPK1, CNKSR1, CBR1 CSF1R 328/4885KDM1A 369/4885MAPT 4495/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.